Drug Trial Radar · NCT05206773
A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
122
Actual
Start
Mar 11, 2022
Primary completion
Dec 17, 2025
Study completion Jan 4, 2027
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jan 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 12-month, parallel treatment, Phase 3, double-blind, randomized, placebo-controlled study to evaluate the effect of venglustat on neuropathic and abdominal pain symptoms of Fabry disease in participants ≥16 years of age with Fabry disease who are treatment-naïve or untreated for at least 6 months. * Study visits will take place approximately every 3 months. * The double-blind period will be followed by an open-label extension (OLE) during which participants who have completed the double-blind period will be treated with venglustat for an additional 12 months or until the Common Study End of Treatment Day (CSEOTD).
Conditions
- Fabry Disease
Interventions
Venglustat (GZ402671)Drug
Pharmaceutical form: Tablet Route of administration: Oral
PlaceboDrug
Pharmaceutical form: Tablet Route of administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline at 6 months in the most bothersome symptom of 3 Fabry Disease Patient-Reported Outcome (FD-PRO) items (neuropathic pain in upper extremities, neuropathic pain in lower extremities, or abdominal pain)Time frame: From baseline to 6 months
- Percent change from baseline at 12 months in the most bothersome symptom of 3 Fabry Disease Patient-Reported Outcome (FD-PRO) items (neuropathic pain in upper extremities, neuropathic pain in lower extremities, or abdominal pain)Time frame: From baseline to 12 months
Locations
50 sites in 21 countries. Site status is shown where the registry gives one.
University of Alabama -The Kirklin Clinic- Site Number : 8400011
Birmingham, Alabama
David Geffen School of Medicine at UCLA- Site Number : 8400006
Los Angeles, California
University of California Irvine Medical Center- Site Number : 8400019
Orange, California
AdventHealth Orlando- Site Number : 8400008
Orlando, Florida
Emory University School of Medicine - Atlanta- Site Number : 8400010
Atlanta, Georgia
WMCHealth Advanced Physician Services- Site Number : 8400001
Hawthorne, New York
Cincinnati Children's Hospital Medical Center- Site Number : 8400013
Cincinnati, Ohio
UPMC Montefiore- Site Number : 8400009
Pittsburgh, Pennsylvania
Renal Disease Research Institute - Dallas - Live Oak Street- Site Number : 8400012
Dallas, Texas
University of Utah Health Hospital- Site Number : 8400005
Salt Lake City, Utah
Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)- Site Number : 8400004
Fairfax, Virginia
Investigational Site Number : 0320002
La Rioja, Argentina
Investigational Site Number : 0320001
Pergamino, Buenos Aires, Argentina
Investigational Site Number : 0320003
Quilmes, Buenos Aires, Argentina
Investigational Site Number : 0360001
Parkville, Victoria, Australia
Investigational Site Number : 0400001
Vienna, Austria
Instituto de Genética e Erros Inatos do Metabolismo- Site Number : 0760002
São Paulo, Brazil
Hospital de Clinicas de Porto Alegre- Site Number : 0760001
Porto Alegre, Rio Grande do Sul, Brazil
Investigational Site Number : 1240003
Calgary, Alberta, Canada
Investigational Site Number : 1240001
Halifax, Nova Scotia, Canada
Investigational Site Number : 1240005
Toronto, Ontario, Canada
Investigational Site Number : 1560001
Beijing, China
Investigational Site Number : 1560003
Shanghai, China
Investigational Site Number : 1560004
Taiyuan, China
Investigational Site Number : 1560006
Zhengzhou, China
Investigational Site Number : 2080001
Copenhagen, Denmark
Investigational Site Number : 2460001
Turku, Finland
Investigational Site Number : 2500001
Garches, France
Investigational Site Number : 2760003
Munich, Germany
Investigational Site Number : 2760001
Würzburg, Germany
Investigational Site Number : 3000003
Athens, Greece
Investigational Site Number : 3000002
Ioannina, Greece
Investigational Site Number : 3800005
Bologna, Italy
Investigational Site Number : 3800001
Naples, Napoli, Italy
Investigational Site Number : 3800004
Rome, Roma, Italy
Investigational Site Number : 3920004
Fukuoka, Japan
Investigational Site Number : 3920003
Tokyo, Japan
Investigational Site Number : 4840002
Mexico City, Mexico
Investigational Site Number : 4840001
Monterrey, Nuevo León, Mexico
Investigational Site Number : 5780001
Bergen, Norway
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.